Current Status of Carbapenem Antibiotics
- Current Status of Carbapenem Antibiotics
- 엘가말; 오창현
- Carbapenems; β-lactams; nosocomial infections; β-lactamases; carbapenemases; community-acquired infections; multidrug resistance; polymicrobial infections; *2010 개인평가 반영완료
- Issue Date
- Current topics in medicinal chemistry
- VOL 10, NO 18, 1882-1897
- β-Lactam antibiotics are the most prescribed antibacterial agents. They comprise more than half of all antibiotics.
They are considered as the cornerstone of the antibiotic armamentarium. By inhibiting bacterial cell wall biosynthesis,
they are highly effective against Gram-positive and Gram-negative bacteria. Antibiotic resistance among Gram-negative
pathogens in hospitals represents a dangerous threat to public health. Since many bacteria have developed resistance to
older agents, new β-lactam antibiotics have been continuously developed. In the late 1970s, a new class of exceptionally
broad-spectrum non-traditional β-lactams, carbapenems, was developed. This review article focuses on the new developments
related to the field of carbapenems for treatment of bacterial infections, especially those caused by Gram-negative
bacteria. The structural features, principal characteristics, and clinical implications of carbapenems including thienamycin,
imipenem/cilastatin, panipenem/betamipron, biapenem, tebipenem, tebipenem pivoxil, meropenem, ertapenem,
doripenem, lenapenem, and tomopenem are discussed herein.
- Appears in Collections:
- KIST Publication > Article
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.